Compare PMTS & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMTS | TNGX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.3M | 4.1B |
| IPO Year | 2015 | 2020 |
| Metric | PMTS | TNGX |
|---|---|---|
| Price | $24.63 | $24.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $32.50 | ★ $45.18 |
| AVG Volume (30 Days) | 227.7K | ★ 2.5M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $312,189,000.00 | $62,384,000.00 |
| Revenue This Year | $11.19 | N/A |
| Revenue Next Year | $8.16 | N/A |
| P/E Ratio | $72.88 | ★ N/A |
| Revenue Growth | 12.27 | ★ 48.29 |
| 52 Week Low | $10.81 | $6.69 |
| 52 Week High | $31.25 | $34.39 |
| Indicator | PMTS | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.21 | 55.12 |
| Support Level | $21.90 | $19.74 |
| Resistance Level | $29.57 | $26.05 |
| Average True Range (ATR) | 0.83 | 1.53 |
| MACD | -0.07 | 0.29 |
| Stochastic Oscillator | 76.00 | 85.77 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit segment, which principally produce secure debit and credit cards and provide card services for U.S. card-issuing financial institutions, including personalization, instant issuance and other payment solutions such as digital push provisioning for mobile wallets; Prepaid Debit, which provides secure packaging solutions, Prepaid Debit Cards, and other integrated prepaid card services to prepaid program managers in the U.S.; and other: principally corporate expenses. The firm generates key revenue from Debit and Credit segment.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.